Evidence map›Paper›PMID 33166282›Full record

ArticlePloS one2020

Sites of vulnerability on ricin B chain revealed through epitope mapping of toxin-neutralizing monoclonal antibodies.

David J Vance, Amanda Y Poon, Nicholas J Mantis

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. B Cell Epitope Mapping by High-Density Competition ELISAs.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  3. Article
  4. Article
  5. The Search for Antidotes Against Ricin.Mini reviews in medicinal chemistry · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

David J VanceDivision of Infectious Disease, New York State Department of Health,Wadsworth Center, Albany, NY, United States of America.
Amanda Y PoonDepartment of Biomedical Sciences, University at Albany School of Public Health, Albany, NY, United States of America.
Nicholas J MantisDivision of Infectious Disease, New York State Department of Health,Wadsworth Center, Albany, NY, United States of America.ORCID 0000-0002-5083-8640
New York State Department of Health · USUniversity at Albany, State University of New York · US

Funding

Development of a Preclinical Assay to Predict Efficacy of Ricin Toxin Subunit VaccinesR01AI125190 · NIAID · WADSWORTH CENTER · PI MANTIS, NICHOLAS J. · 2016 to 2020
$4.1M
NIAID NIH HHS HHSN272201400021CNIAID NIH HHS R01 AI125190
6 · The paper itself

Abstract

Ricin toxin's B subunit (RTB) is a multifunctional galactose (Gal)-/N-acetylgalactosamine (GalNac)-specific lectin that promotes uptake and intracellular trafficking of ricin's ribosome-inactivating subunit (RTA) into mammalian cells. Structurally, RTB consists of two globular domains (RTB-D1, RTB-D2), each divided into three homologous sub-domains (α, β, γ). The two carbohydrate recognition domains (CRDs) are situated on opposite sides of RTB (sub-domains 1α and 2γ) and function non-cooperatively. Previous studies have revealed two distinct classes of toxin-neutralizing, anti-RTB monoclonal antibodies (mAbs). Type I mAbs, exemplified by SylH3, inhibit (~90%) toxin attachment to cell surfaces, while type II mAbs, epitomized by 24B11, interfere with intracellular toxin transport between the plasma membrane and the trans-Golgi network (TGN). Localizing the epitopes recognized by these two classes of mAbs has proven difficult, in part because of RTB's duplicative structure. To circumvent this problem, RTB-D1 and RTB-D2 were expressed as pIII fusion proteins on the surface of filamentous phage M13 and subsequently used as "bait" in mAb capture assays. We found that SylH3 captured RTB-D1 (but not RTB-D2) in a dose-dependent manner, while 24B11 captured RTB-D2 (but not RTB-D1) in a dose-dependent manner. We confirmed these domain assignments by competition studies with an additional 8 RTB-specific mAbs along with a dozen a single chain antibodies (VHHs). Collectively, these results demonstrate that type I and type II mAbs segregate on the basis of domain specificity and suggest that RTB's two domains may contribute to distinct steps in the intoxication pathway.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingChlorocebus aethiopsEpitope MappingEpitopesHeLa CellsHumansProtein ConformationProtein SubunitsRicinToxins, BiologicalVero CellsAntibodies, MonoclonalAntibodies, NeutralizingEpitopesProtein SubunitsRicinToxins, Biological

Identifiers

PMID33166282
PMCPMC7652295
OpenAlexW3104651328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.